← Back

Wire · regulatory

FDA Clears IVD Tests, Systems from Hamamatsu, Roche, Cepheid, Siemens Healthineers ...

Published

14 August 2026

Topic

regulatory

Sectors

Diagnostics

Geography

United States

Source

Read at 360dx.com

Verified

Fusion42 · 14 August 2026 · Fusion42 review

The US FDA granted over a dozen 510(k) clearances in July to in vitro diagnostic products from Hamamatsu, Roche, Cepheid, Siemens Healthineers, and others, covering digital pathology systems, clinical chemistry tests, immunoassays, antimicrobial susceptibility tests, and molecular assays.

This Wire brief sits within Fusion42's coverage of Diagnostics.

◆ The Wire takeaway

Your diagnostics product can gain quicker market access as several major players just cleared their tests with the FDA, signalling faster approval routes are available. Now is the time to align regulatory strategy to capitalise on this smoother entry path.

Coverage

1 source · 14 Aug 2026

Related on Wire

Topics

Diagnosticsfdaivddiagnosticsregulatory-approvalclinical-chemistryimmunoassays